Sun Pharma to discontinue non-strategic business units
As a part of its integration process with Ranbaxy Laboratories, Sun Pharma is likely to discontinue certain non-strategic businesses to have a smooth and sustainable transition. Sun Pharma had acquired Ranbaxy in a $4 billion deal last year.
As implied by the Sun Pharma Managing Director Dilip Shanghvi said the decision to discontinue the non-strategic part of the business is also coupled with the fact of the company’s foreseeing a loss due to integration charges. However, Sun Pharma eyes synergy benefits of $300 million (around Rs 2,000 crore) by 2017-18 from the merger.
Sun Pharma has also officially reported to the press that it expects its revenues and net profit to be adversely hit in the short term due to supply constraints at Halol facility in Gujarat and high expenses arising out of Ranbaxy integration as well as remedial actions.
Addressing the company's shareholders during the annual general meeting (AGM) on the weekend, Dilip Shanghvi said that in the near term and especially for 2015-16 fiscal, the company's overall growth in revenues and net profit will be adversely impacted due to temporary supply constraints at Halol plant.
The US Food and Drug Administration (USFDA) had pointed out certain current good manufacturing practice (cGMP) deviations at the company's Halol facility.
The company's profitability is also expected to be hit by certain expenses and charges arising out of Ranbaxy integration as well as remedial actions, he added.
"Post the consolidation in this fiscal, the company will be better placed to pursue higher than industry growth in subsequent years," Shanghvi said.
Shanghvi said the "remediation process at the erstwhile Ranbaxy facilities, which were found to be non-compliant in the past, also continues as per the plan".
While significant efforts to make these facilities compliant are on, this will be a time-consuming process, he added.
Currently, all the four manufacturing facilities of Ranbaxy - Mohali and Toansa in Punjab, Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh - have been banned by the USFDA from export of drugs to the US market.
While Paonta Sahib and Dewas facilities have been under US import alert since 2008, the US health regulator has since banned the other two as well.
The company is also in the process of implementig corrective steps at Halol facility.
As implied by the Sun Pharma Managing Director Dilip Shanghvi said the decision to discontinue the non-strategic part of the business is also coupled with the fact of the company’s foreseeing a loss due to integration charges. However, Sun Pharma eyes synergy benefits of $300 million (around Rs 2,000 crore) by 2017-18 from the merger.
Sun Pharma has also officially reported to the press that it expects its revenues and net profit to be adversely hit in the short term due to supply constraints at Halol facility in Gujarat and high expenses arising out of Ranbaxy integration as well as remedial actions.
Addressing the company's shareholders during the annual general meeting (AGM) on the weekend, Dilip Shanghvi said that in the near term and especially for 2015-16 fiscal, the company's overall growth in revenues and net profit will be adversely impacted due to temporary supply constraints at Halol plant.
The US Food and Drug Administration (USFDA) had pointed out certain current good manufacturing practice (cGMP) deviations at the company's Halol facility.
The company's profitability is also expected to be hit by certain expenses and charges arising out of Ranbaxy integration as well as remedial actions, he added.
"Post the consolidation in this fiscal, the company will be better placed to pursue higher than industry growth in subsequent years," Shanghvi said.
Shanghvi said the "remediation process at the erstwhile Ranbaxy facilities, which were found to be non-compliant in the past, also continues as per the plan".
While significant efforts to make these facilities compliant are on, this will be a time-consuming process, he added.
Currently, all the four manufacturing facilities of Ranbaxy - Mohali and Toansa in Punjab, Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh - have been banned by the USFDA from export of drugs to the US market.
While Paonta Sahib and Dewas facilities have been under US import alert since 2008, the US health regulator has since banned the other two as well.
The company is also in the process of implementig corrective steps at Halol facility.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.